Last update 21 Nov 2024

Cinmetacin

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

INDOLACIN, 吲哚拉辛

Target-

Mechanism-

Therapeutic Areas

Immune System DiseasesInfectious DiseasesSkin and Musculoskeletal Diseases

Active Indication

Ankylosing SpondylitisRheumatoid Arthritis

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure

Molecular FormulaC21H19NO4

InChIKeyNKPPORKKCMYYTO-UHFFFAOYSA-N

CAS Registry20168-99-4

100 Clinical Results associated with Cinmetacin

100 Translational Medicine associated with Cinmetacin

100 Patents (Medical) associated with Cinmetacin

Literatures (Medical) associated with Cinmetacin

01 Sep 1995·Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology

[The effect of indolacin in rat periapical lesion and radioimmunoassay determination of prostaglandin E2].

Article

Author: Li, S ; Li, Y

01 Oct 1994·Journal of Chromatography B: Biomedical Sciences and Applications

Gas chromatographic—electron-impact chemical ionization mass spectrometric identification of cinmetacin and its metabolites in human urine

Article

Author: Jong-Sei Park ; Chang-No Yoon ; Myung-Soo Kim ; Woon-Sun Ahn ; Seung-Woon Myung

Cinmetacin and its three metabolites were identified by gas chromatography-electron-impact positive-ion chemical ionization-negative chemical ionization mass spectrometry. After a single oral dose of 30 mg of cinmetacin to a healthy man, urine was collected and hydrolysed. The three metabolites were identified as O-desmethylated, N-descinnamoyl and C-C double bond reduced cinmetacins. The identification of cinmetacin metabolites in human urine was established by comparison of their GC retention times and electron impact and methane chemical ionization mass spectra with those of the synthesized authentic standards.

01 Jan 1988·Arzneimittel-Forschung

Plasma pharmacokinetics of cinmetacin following oral administration in healthy volunteers.

Article

Author: Del Tacca, M ; Acerbi, D ; Danesi, R ; Ducci, M

The pharmacokinetics of a single 600 mg oral dose of 1-cinnamoyl-2-methyl-5-methoxy-3-indolylacetic acid (cinmetacin, Cindomet) was studied in 8 healthy volunteers of both sexes. Plasma levels of the drug were assayed by using an HPLC technique ad hoc devised. Following administration, the Cmax was reached at the 2nd h in 7 out of 8 subjects with an average value of 18.19 micrograms/ml; 12 h after the dose (last sampling time) appreciable plasma levels of cinmetacin were measured, corresponding to 17.2% of the maximum average concentration. The mean values +/- S.E. concerning the elimination half-life, the total volume of distribution, the total plasma clearance and the total area under the curve were 3.80 +/- 0.21 h, 0.28 +/- 0.03 l/kg, 0.051 +/- 0.005 l/kg/h, and 125.64 +/- 15.97 micrograms.h/ml, respectively. The plasma decay of cinmetacin was monophasic and the data were interpreted according to a one-compartment open model. Overall results indicate that cinmetacin is well and rapidly absorbed orally and widely distributed in body fluids.

100 Deals associated with Cinmetacin

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Ankylosing Spondylitis	CN	-	-
Rheumatoid Arthritis	CN	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Cinmetacin

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation